Andere Sprachen Blueprint Medicines Corporation

Aktien

A14SDD

US09627Y1091

BPMC

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:26:17 02.05.2024			% 5 Tage	% 1. Jan.
106.9 ^USD	+12.71%		+17.16%	+15.24%

18:14	BLUEPRINT MEDICINES CORPORATION : Wedbush bekräftigt seine Kaufempfehlung	ZM
16:33	Aktien von Blueprint Medicines steigen nach Q1 auf Nettogewinn, Umsatz steigt	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	16:33
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M	13:36
Blueprint Medicines: Q1 Earnings Snapshot	13:12
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	13:10
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	13:00
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024	18.04.
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	11.04.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.04.
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	22.03.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.03.
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	01.03.
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	26.02.
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	23.02.
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	23.02.
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	22.02.
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	15.02.
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	15.02.
Blueprint Medicines: Q4 Earnings Snapshot	15.02.
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M	15.02.
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Blueprint Medicines Corporation

Aktien

A14SDD

US09627Y1091

BPMC

Andere Sprachen

Filter